Search
Platelet Lysate
go.drugbank.com/drugs/DB15869Investigational[A220188] It is extracted through lysis of the plasma membrane of platelets. Because white cell antigens are low in prepared lysate, there is a minimized likelihood of immune responses. … Platelet lysate is an acellular compound composed of platelet proteins while also being void of cellular debris, thus making the lysate rich with growth factors.
Epicept NP-1
go.drugbank.com/drugs/DB05492InvestigationalEpiCept NP-1 Cream is a patented formulation containing two FDA-approved drugs, amitriptyline (a widely-used antidepressant) and ketamine (an NMDA antagonist that is used as an anesthetic). … Peripheral neuropathies are medical conditions caused by damage to the nerves in the peripheral nervous system.
Synonyms: Epicept NP-1DDP-225
go.drugbank.com/drugs/DB05642InvestigationalNoradrenaline and serotonin are neurotransmitters that are known to be involved in the control of the gastrointestinal system. … DDP225 is both a noradrenaline reuptake inhibitor and a serotonin type 3 receptor (5-HT3) antagonist.
Categories: Heterocyclic Compounds, 1-RingLX6171
go.drugbank.com/drugs/DB05180InvestigationalLX6171 is an oral drug candidate that was generated by Lexicon medicinal chemists and is being developed to treat disorders characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia
Oblimersen
go.drugbank.com/drugs/DB13811InvestigationalCategories: Compounds used in a research, industrial, or household setting1,10-Phenanthroline
go.drugbank.com/drugs/DB02365InvestigationalSynonyms: O-PhenanthrolineCategories: Compounds used in a research, industrial, or household setting, Heterocyclic Compounds, 3-RingPPI-1019
go.drugbank.com/drugs/DB05832InvestigationalApan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.
NRP409
go.drugbank.com/drugs/DB05235ExperimentalNRP409 is a triiodothyronine (T3) hormone, being investigated by New River Pharmaceuticals as a treatment for patients with primary hypothyroidism.
NUC B1000
go.drugbank.com/drugs/DB05242ExperimentalOn January 11, 2008, it was announced that NUC B1000 was entering a phase 1 human safety study of its experimental treatment for chronic Hepatitis B virus (HBV) infection. … NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid